A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 50,400 shares of BCLI stock, worth $17,136. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,400
Previous 74,000 31.89%
Holding current value
$17,136
Previous $19,000 47.37%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$2.0 - $3.2 $55,576 - $88,921
27,788 Added 211.03%
40,956 $84,000
Q1 2023

May 15, 2023

SELL
$1.43 - $3.3 $4,713 - $10,876
-3,296 Reduced 20.02%
13,168 $43,000
Q4 2022

Feb 14, 2023

SELL
$1.37 - $3.39 $19,923 - $49,300
-14,543 Reduced 46.9%
16,464 $27,000
Q3 2022

Nov 14, 2022

BUY
$2.55 - $4.3 $13,571 - $22,884
5,322 Added 20.72%
31,007 $137,000
Q2 2022

Aug 15, 2022

BUY
$2.71 - $3.6 $4,243 - $5,637
1,566 Added 6.49%
25,685 $70,000
Q1 2022

May 16, 2022

BUY
$2.92 - $4.19 $22,305 - $32,007
7,639 Added 46.35%
24,119 $81,000
Q3 2021

Nov 15, 2021

SELL
$3.14 - $4.09 $108,917 - $141,869
-34,687 Reduced 67.79%
16,480 $54,000
Q2 2021

Aug 16, 2021

BUY
$3.01 - $4.01 $34,955 - $46,568
11,613 Added 29.36%
51,167 $194,000
Q1 2021

May 17, 2021

BUY
$3.46 - $7.88 $94,506 - $215,234
27,314 Added 223.15%
39,554 $151,000
Q4 2019

Feb 14, 2020

SELL
$3.62 - $4.29 $16,557 - $19,622
-4,574 Reduced 27.2%
12,240 $52,000
Q2 2019

Aug 14, 2019

BUY
$3.59 - $4.3 $10,421 - $12,482
2,903 Added 20.87%
16,814 $66,000
Q1 2019

May 15, 2019

BUY
$3.37 - $4.34 $10,258 - $13,210
3,044 Added 28.01%
13,911 $0
Q4 2018

Feb 14, 2019

BUY
$2.98 - $3.9 $32,383 - $42,381
10,867 New
10,867 $38,000
Q1 2018

May 11, 2018

SELL
$3.01 - $3.77 $45,252 - $56,678
-15,034 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$2.96 - $4.42 $698 - $1,043
236 Added 1.59%
15,034 $59,000
Q3 2017

Nov 09, 2017

BUY
$3.98 - $4.36 $58,896 - $64,519
14,798
14,798 $61,000

Others Institutions Holding BCLI

About BRAINSTORM CELL THERAPEUTICS INC.


  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $12.4M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.